ProMed Pharma Acquires Plymouth Pharmaceutical Plant
A pharmaceutical manufacturing facility in Plymouth has a new owner.
The 28,000-square-foot state-of-the-art facility, located at 2200 Niagara Ln. N., has been acquired by Maple Grove-based ProMed Pharma.
The facility was previously owned by Taiwan-based Bora Pharmaceuticals, which recently announced a major expansion in Maple Grove at the former Upsher-Smith plant.
ProMed Pharma is a leader in polymer-based drug delivery solutions and controlled release therapies.
“The acquisition of this facility marks a significant milestone in our growth strategy,” said Clint Schneider, president of ProMed Pharma, in a press release.
ProMed Pharma also has other facilities in Plymouth.
According to the press release, the new Plymouth acquisition allows the company to expand and enhance its commercial manufacturing capabilities to better serve companies in the pharmaceutical and biotech industries.
The facility is expected to be fully operational by mid-2026, the release stated.
